Correction: Angiotensin-Converting Enzyme (ACE) 2 Overexpression Ameliorates Glomerular Injury in a Rat Model of Diabetic Nephropathy: A Comparison with ACE Inhibition (Molecular Medicine, (2011), 17, 1-2, (59-69), 10.2119/molmed.2010.00111);Angiotensin-converting enzyme (ACE) 2 overexpression ameliorates glomerular injury in a rat model of diabetic nephropathy: A comparison with ACE inhibition

Molecular Medicine

Volumn 17, Issue 1-2, 2011, Pages 59-69

  Liu, Chun Xi ^a,b   Hu, Qin ^a   Wang, Yan ^a   Zhang, Wei ^a   Ma, Zhi Yong ^a   Feng, Jin Bo ^a   Wang, Rong ^a   Wang, Xu Ping ^a   Dong, Bo ^a   Gao, Fei ^a   Zhang, Ming Xiang ^a   Zhang, Yun ^a  

^a SHANDONG UNIVERSITY   (China)

^b Tsinghua University   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALBUMIN; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN II; BENAZEPRIL; CITRATE SODIUM; COLLAGEN TYPE 4; CREATININE; GREEN FLUORESCENT PROTEIN; MALONALDEHYDE; STREPTOZOCIN; SUPEROXIDE DISMUTASE; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN;

ACE2 GENE; ALBUMINURIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCHEMISTRY; CELL PROLIFERATION; COLLAGEN SYNTHESIS; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE; GENE OVEREXPRESSION; GENE THERAPY; GENETIC TRANSFECTION; GLOMERULOSCLEROSIS; KIDNEY FUNCTION; MALE; MESANGIUM CELL; NONHUMAN; OXIDATIVE STRESS; PHYSICAL PERFORMANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RENAL PROTECTION; STREPTOZOCIN DIABETES; SYSTOLIC BLOOD PRESSURE; WISTAR RAT;

EID: 78651497653     PISSN: 10761551     EISSN: 15283658     Source Type: Journal    
DOI: 10.1186/s10020-022-00482-9     Document Type: Erratum

References (42)

1. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. (2000) A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril insensitive carboxypeptidase. J. Biol. Chem. 275:33238-33243.
2. Donoghue M, et al. (2000) A novel angiotensinconverting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ. Res. 87:E1-E9.
3. Vickers C, et al. (2002) Hydrolysis of biological peptides by human angiotensin-converting enzyme- related carboxypeptidase. J. Biol. Chem. 277:14838-14843.
4. Oudit GY, et al. (2006) Loss of angiotensinconverting enzyme-2 leads to the late development of angiotensin II-dependent glomerulosclerosis. Am. J. Pathol. 168:1808-1820.
5. Crackower MA, et al. (2002) Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 417:822-828.
6. Yamamoto K, et al. (2006) Deletion of angiotensinconverting enzyme 2 accelerates pressure overload- induced cardiac dysfunction by increasing local angiotensin II. Hypertension 47:718-726.
7. Diez-Freire C, et al. (2006) ACE2 gene transfer attenuates hypertension-linked pathophysiological changes in the SHR. Physiol. Genom. 27:12-19.
8. Dong B, et al. (2008) Overexpression of ACE2 enhances plaque stability in a rabbit model of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 28:1270-6.
9. Rentzsch B, et al. (2008) Transgenic angiotensinconverting enzyme 2 overexpression in vessels of SHRSP rats reduces blood pressure and improves endothelial function. Hypertension 52:967-973.
10. Cooper ME. (1998) Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 352:213-219.
11. Parving HH, Rossing P. (2001) Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes. Diabetes Care 24:177-180.
12. Tikellis C, et al. (2008) ACE2 deficiency modifies renoprotection afforded by ACE inhibition in experimental diabetes. Diabetes 57:1018-1025.
13. Simões e Silva AC, Pinheiro SV, Pereira RM, Ferreira AJ, Santos RA. (2006) The therapeutic potential of angiotensin-(1-7) as a novel reninangiotensin system mediator. Mini Rev. Med. Chem. 6:603-609.
14. Santos RA, Ferreira AJ. (2007) Angiotensin-(1-7) and the renin-angiotensin system. Curr. Opin. Nephrol. Hypertens. 16:122-128.
15. Ferrario CM, Trask AJ, Jessup JA. (2005) Advances in biochemical and functional roles of angiotensin- converting enzyme 2 and angiotensin- (1-7) in regulation of cardiovascular function. Am. J. Physiol. 289:H2281-H2290.
16. Douglas JG. (1987) Angiotensin receptor subtypes of the kidney cortex. Am. J. Physiol. 253:F1-F7.
17. Lely AT, Hamming I, van Goor H, Navis GJ. (2004) Renal ACE2 expression in human kidney disease. J. Path. 204:587-593.
18. Reich HN, Oudit GY, Penninger JM, Scholey JW, Herzenberg AM. (2008) Decreased glomerular and tubular expression of ACE2 in patients with type 2 diabetes and kidney disease. Kidney Int. 74:1610-1616.
19. Soler MJ, Wysocki J, Ye M, Lloveras J, Kanwar Y, Batlle D. (2007) ACE2 inhibition worsens glomerular injury in association with increased ACE expression in streptozotocin-induced diabetic mice. Kidney Int. 72:614-623.
20. Wong DW, Oudit GY, Reich H, et al. (2007) Loss of angiotensin-converting enzyme-2 (Ace2) accelerates diabetic kidney injury. Am. J. Pathol. 171:438-451.
21. Ye M, Wysocki J, William J, Soler MJ, Cokic I, Batlle D. (2006) Glomerular localization and expression of angiotensin-converting enzyme 2 and angiotensin-converting enzyme: implications for albuminuria in diabetes. J. Am. Soc. Nephrol. 17:3067-375.
22. Oudit GY, et al. Human recombinant ACE2 reduces the progression of diabetic nephropathy. Diabetes 59:529-538.
23. Zheng M, et al. (2009) Rosiglitazone protects diabetic rats against kidney disease through the suppression of renal moncyte chemoattractant protein-1 expression. J. Diabetes Complications 23:124-129.
24. Zhang YW, Xie D, Xia B, Zhen RT, Liu IM, Cheng JT. (2006) Suppression of transforming growth factor-beta1 gene expression by Danggui buxue tang, a traditional Chinese herbal preparation, in retarding the progress of renal damage in streptozotocin- induced diabetic rats. Horm Metab Res 38:82-88.
25. Wysocki J, et al. (2006) ACE and ACE2 activity in diabetic mice. Diabetes 55:2132-2139.
26. Boffa JJ, Tharaux PL, Placier S, Ardaillou R, Dussaule JC, Chatziantoniou C. (1999) Angiotensin II activates collagen type I gene in the renal vasculature of transgenic mice during inhibition of nitric oxide synthesis: evidence for an endothelinmediated mechanism. Circulation 100:1901-1908.
27. Tesch GH, Allen TJ. (2007) Rodent models of streptozotocin-induced diabetic nephropathy. Nephrology (Carlton) 12:261-266.
28. Kelly DJ, Skinner SL, Gilbert RE, Cox AJ, Cooper ME, Wilkinson-Berka JL. (2000) Effects of endothelin or angiotensin II receptor blockade on diabetes in the transgenic (mRen-2)27 rat. Kidney Int. 57:1882-1894.
29. Anderson S, Jung FF, Ingelfinger JR. (1993) Renal renin-angiotensin system in diabetes: functional, immunohistochemical, and molecular biological correlations. Am. J. Physiol. 265:F477-F486.
30. Oudit GY, et al. (2007) Angiotensin II-mediated oxidative stress and inflammation mediate the age-dependent cardiomyopathy in ACE2 null mice. Cardiovasc. Res. 75:29-39.
31. Allred AJ, Diz DI, Ferrario CM, Chappell MC. (2000) Pathways for angiotensin-(1-7) metabolism in pulmonary and renal tissues. Am. J. Physiol. Renal. Physiol. 279:F841-F850.
32. Tikellis C, et al. (2003) Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy. Hypertension 41:392-397.
33. Ziyadeh FN, Wolf G. (2008) Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy. Curr. Diabetes Rev. 4:39-45.
34. Wolf G. (2006) Renal injury due to renin-angiotensin- aldosterone system activation of the transforming growth factor-beta pathway. Kidney Int. 70:1914-1919.
35. Ziyadeh FN. (2004) Mediators of diabetic renal disease: the case for tgf-Beta as the major mediator. J. Am. Soc. Nephrol. 15 Suppl 1:S55-S57.
36. Kanwar YS, et al. (2008) Diabetic nephropathy: mechanisms of renal disease progression. Exp Biol Med (Maywood) 233:4-11.
37. Riviere G, et al. (2005) Angiotensin-converting enzyme 2 (ACE2) and ACE activities display tissue-specific sensitivity to undernutritionprogrammed hypertension in the adult rat. Hypertension 46:1169-1174.
38. Lewis EJ, Lewis JB. (2003) Treatment of diabetic nephropathy with angiotensin II receptor antagonist. Clin. Exp. Nephrol. 7:1-8.
39. Masson R, et al. (2009) Onset of experimental severe cardiac fibrosis is mediated by overexpression of angiotensin-converting enzyme 2. Hypertension 53:694-700.
40. Shao Y, He M, Zhou L, Yao T, Huang Y, Lu LM. (2008) Chronic angiotensin (1-7) injection accelerates STZ-induced diabetic renal injury. Acta. Pharmacol. Sin. 29:829-37.
41. Ye M, Wysocki J, Naaz P, Salabat MR, LaPointe MS, Batlle D. (2004) Increased ACE 2 and decreased ACE protein in renal tubules from diabetic mice: a renoprotective combination? Hypertension 43:1120-25.
42. Kim HJ, et al. (2004) Combined therapy of cilazapril and losartan has no additive effects in ameliorating adriamycin-induced glomerulopathy. Nephron 97:58-65.